Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) - Candlesense
CGTX Financing

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

(NASDAQ:CGTX) PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed its previously announced registered direct offering of 14,700,000 shares of common stock at a purchase price of $2.05 per share. Gross proceeds from the offering were approximately $30 million, before deducting placement agent fees and other offering expenses.

Related Questions

How will the $30 million capital raise affect dilution and future earnings per share? What are the expected timelines and milestones for Phase 3 of Zervimesine (CT1812) and how might they impact the stock? Who are the two new fundamental institutional investors and does their participation signal increased credibility for Cognition’s pipeline?
Find similar articles on Candlesense globenewswire